TABLE 3.

Adjusted changes in arterial stiffness assays in the telmisartan/rosuvastatin SPC and telmisartan monotherapy groups

Variables	Visit		Telmisartan (N = 33)	Telmisartan/rosuvastatin (N = 36)	LS mean difference [95% CI]	p‐value
Brachial‐ankle pulse wave velocity (cm/s)	Baseline	Mean (SD)	1542.85(263.70)	1672.57(371.72)		.130 b
	Week 16	Mean (SD)	1586.12(297.45)	1591.75(272.16)
	Change a	LS mean (SE) c	19.70(34.15)	−66.40(33.14) d	−86.10 [−182.09, 9.90]	.078
Augmentation index (%)	Baseline	Mean (SD)	35.91(26.15)	33.67(18.32)		.943 b
	Week 16	Mean (SD)	33.85(26.55)	33.94(19.06)
	Change a	LS mean (SE) c	−1.99(1.57)	0.22(1.50)	2.21 [−2.14, 6.56]	.314

Abbreviations: DBP, diastolic blood pressure; LS, least square; PP, pulse pressure; SBP, systolic blood pressure; SE, standard error.

^a Change = (Value at week 16) − (value at baseline).

^b Difference between control and treatment group (Wilcoxon rank sum test).

^c Wilcoxon rank sum test.

^d N = 35.